ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0843

External Validation and Extension of Population-Based Systemic Lupus Erythematosus Risk Prediction Models Using Genetics, and Lifestyle and Environmental Factors

Jacob J.E. Koopman1, Jing Cui1, Hongshu Guan1, Emma Stevens1, Emily Oakes1 and Karen Costenbader2, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital/ Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2024

Keywords: genetics, risk factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Abstracts: Epidemiology & Public Health I

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Many genetic and environmental risk factors for SLE are now known. We have developed SLE risk prediction models, incorporating known genetic, lifestyle, and environmental risk factors in the Nurses’ Health Study cohorts (NHS), with area under the receiver operating characteristic (AUC) 0.76 (95% CI 0.72-0.81) for SLE among women. (Cui J, Seminars Art Rheum 2023). Here, we aimed to externally validate and extend these models in a separate population.

Methods: We performed a nested case-control study in the Mass General Brigham (MGB) Biobank, containing an enrollment health assessment survey, genome-wide genotyping, and linked electronic medical record (EMR) data on 149,680 consented patients. Diagnosed SLE cases met Updated 1997 ACR and/or 2019 EULAR/ACR criteria. SLE patients with genotyping were selected and matched by age (± 4 years), sex, and race/ethnicity to patients without SLE with similar data. As in our prior NHS models, we collected data on risk factors (from prior to SLE diagnosis or matched index date), including current/recent smoking, low/no alcohol use, highest educational level, body mass index, major depression, among females, age at menarche, oral contraceptive use, and menopausal status/postmenopausal hormone use. Our SLE weighted genetic risk score (wGRS) used 86 known single nucleotide polymorphisms (SNPs) and 10 classical HLA alleles. We compared 3 multivariable risk prediction models, for all SLE and for dsDNA+ SLE, and for females only and then including males (without female reproductive factors): Model 1. SLE wGRS; Model 2. current/recent smoking, low/no alcohol use, obesity, depression, race/ethnicity, education status and, among females, early menarche, oral contraceptive use, and menopause/postmenopausal hormones; Model 3. Models 1+2. All models additionally adjusted for matching factors.

Results: We matched 535 patients with SLE (90% female) to 2,135 (90% female) patients without. Index date characteristics are shown in Table 1. Models 1-3 for all SLE among women yielded AUCs 0.69 (95%CI 0.67-0.72), 0.74 (95%CI 0.72-0.77), 0.82 (95% CI 0.79-0.84). Model 3 based on genetics, lifestyle and environmental factors had best discrimination for both SLE and ds+DNA SLE in females only and for both sexes (AUC 0.81 [95% CI 0.78-0.83]).

Conclusion: Our model including SLE wGRS, lifestyle, and environmental risk factors accurately classified future SLE risk with AUC of 0.81-0.82 in this external population. As genetic data are increasingly available and risk factors easily assessed, this or similar SLE prediction model could be feasibly employed for screening at-risk populations for prevention interventions.

Supporting image 1

Supporting image 2

Figure 1A-D. Areas Under the Curve (AUC) for SLE Risk Prediction among 2144 females and 259 males within the Mass General Brigham Biobank (A) All SLE Risk Prediction Model, females only, (B) dsDNA+ SLE, females only, (C) SLE, females and males, and (D) dsDNA+ SLE, females and males


Disclosures: J. Koopman: None; J. Cui: None; H. Guan: None; E. Stevens: None; E. Oakes: None; K. Costenbader: Amgen, 2, 5, AstraZeneca, 5, Bain HealthSciences, 2, Bristol-Myers Squibb(BMS), 2, Cabaletta Bio, 2, 5, Exagen, 5, Gilead, 5, Glaxo Smith Kline, 2, 5, Merck, 5.

To cite this abstract in AMA style:

Koopman J, Cui J, Guan H, Stevens E, Oakes E, Costenbader K. External Validation and Extension of Population-Based Systemic Lupus Erythematosus Risk Prediction Models Using Genetics, and Lifestyle and Environmental Factors [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/external-validation-and-extension-of-population-based-systemic-lupus-erythematosus-risk-prediction-models-using-genetics-and-lifestyle-and-environmental-factors/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/external-validation-and-extension-of-population-based-systemic-lupus-erythematosus-risk-prediction-models-using-genetics-and-lifestyle-and-environmental-factors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology